Sign In
Buy CLDX
$33.41
+0.98 (+3.02%)
At Close: Jun 22, 2026
Alnylam's Vutrisiran Gets Fast Track Tag for hATTR Amyloidosis
03:15pm, Wednesday, 15'th Apr 2020
The FDA confers a Fast Track status on Alnylam's (ALNY) RNAi therapeutic vutrisiran for treating adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Moleculin (MBRX) Looks Good: Stock Adds 5.3% in Session
12:37pm, Tuesday, 14'th Apr 2020
Moleculin (MBRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Immunomedics' Sacituzumab Govitecan Gets Fast Track Tag for UC
03:36pm, Wednesday, 08'th Apr 2020
The FDA bestows a fast track status on Immunomedics' (IMMU) sacituzumab govitecan for treating adult patients with locally advanced or metastatic urothelial cancer (mUC).
Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study
04:37pm, Tuesday, 07'th Apr 2020
Axsome's (AXSM) AXS-07 achieves both regulatory co-primary endpoints in the phase III INTERCEPT study for the early treatment of migraine.
Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue
03:14pm, Tuesday, 07'th Apr 2020
Mallinckrodt (MNK) begins rolling submission of BLA for StrataGraft regenerative skin tissue therapy to the FDA for addressing adult patients with deep partial-thickness thermal burns. Stock rises.
Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue
03:14pm, Tuesday, 07'th Apr 2020
Mallinckrodt (MNK) begins rolling submission of BLA for StrataGraft regenerative skin tissue therapy to the FDA for addressing adult patients with deep partial-thickness thermal burns. Stock rises.
UroGen (URGN) Looks Good: Stock Adds 8.1% in Session
12:53pm, Monday, 06'th Apr 2020
UroGen (URGN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
UroGen (URGN) Looks Good: Stock Adds 8.1% in Session
12:53pm, Monday, 06'th Apr 2020
UroGen (URGN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Mesoblast's (MESO) BLA for Ryoncil Gets FDA Priority Review
06:42am, Friday, 03'rd Apr 2020
The FDA accepts Mesoblast's (MESO) BLA for Ryoncil (remestemcel-L) under a priority review to treat children with steroid-refractory acute graft versus host disease. A decision is pending on Sep 30.
Mesoblast's (MESO) BLA for Ryoncil Gets FDA Priority Review
06:42am, Friday, 03'rd Apr 2020
The FDA accepts Mesoblast's (MESO) BLA for Ryoncil (remestemcel-L) under a priority review to treat children with steroid-refractory acute graft versus host disease. A decision is pending on Sep 30.
Analysts Are Bullish on These Healthcare Stocks: Celldex (CLDX), Evolus (EOLS)
11:15am, Friday, 27'th Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Celldex (CLDX), Evolus (EOLS) and Vascular Biogenics (VBLT)
Analysts Are Bullish on These Healthcare Stocks: Celldex (CLDX), Evolus (EOLS)
11:15am, Friday, 27'th Mar 2020
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Celldex (
CLDX
–
Research Report
), Evolus (
EOLS
–
Research Report
) and Vascular Biogenics (
VBLT
Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2019 Results
08:01pm, Thursday, 26'th Mar 2020
HAMPTON, N.J., March 26, 2020 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31,.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) * Biomerica, Inc. (NASDAQ: BMRA) * Centogene NV (
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 19.)
Biomerica, Inc. (NASDAQ...
